Actinic reticuloid
ICD-10 L57.1 is a billable code used to indicate a diagnosis of actinic reticuloid.
Actinic reticuloid is a rare skin condition characterized by a photosensitive dermatitis that results from chronic sun exposure, primarily affecting individuals with a history of actinic keratosis or other sun-induced skin changes. Clinically, it presents as erythematous patches and plaques, often with a reticular pattern, typically on sun-exposed areas such as the face, neck, and arms. The condition is thought to be an immune-mediated response to solar damage, leading to a lymphocytic infiltrate in the dermis. Disease progression can vary, with some patients experiencing chronic symptoms and others developing more severe manifestations, including potential transformation into skin malignancies. Diagnosis is primarily clinical, supported by a thorough patient history and physical examination, and may be confirmed through skin biopsy showing characteristic histopathological changes. Differential diagnoses include other forms of dermatitis, such as eczema or psoriasis, and conditions like cutaneous T-cell lymphoma, necessitating careful evaluation.
Standard ICD-10-CM documentation requirements apply
Various clinical presentations within this specialty area
Follow specialty-specific billing guidelines
Standard ICD-10-CM documentation requirements apply
Various clinical presentations within this specialty area
Follow specialty-specific billing guidelines
L57.1 specifically covers actinic reticuloid, a condition resulting from chronic sun exposure leading to photosensitive dermatitis. It is essential to differentiate it from actinic keratosis and other dermatitis types.
L57.1 should be used when the clinical presentation aligns with actinic reticuloid, particularly when there is a history of sun exposure and characteristic skin findings. It is crucial to differentiate it from other dermatitis codes based on clinical and histological evidence.
Documentation should include a detailed patient history of sun exposure, clinical findings of erythematous patches, and any biopsy results showing lymphocytic infiltrate. Clear documentation of the treatment plan and response is also necessary.
